Objective: Validation of the LT-SYS quantitative in vitro copper assay on a Roche Cobas 8000 c502 analyzer and comparison with a BIOMED assay on a Roche Cobas Mira analyzer.
While Morbus Wilson is a rare genetic disorder with an estimated prevalence of 1:30,000, psychiatric and neurological symptoms can be quite unspecific, and thus the laboratory assessment of plasma copper concentrations is crucial for the differential diagnosis of this disease. 3 Plasma copper deficiencies can also be caused by malabsorption syndromes, general malnourishment, or insufficient quantities of copper supplement in patients dependent on prolonged nutritional support. Healthy adult males have been reported to have plasma copper values between 10 and 22 mmol/L, while pregnant women and women taking oral contraceptives can have considerable higher levels of plasma copper, with up to 31 mmol/L.
2,4
Methods for the analysis of plasma or serum copper concentrations range from atomic absorption spectrophotometry over mass spectrometry to the more commonly used photometry. 5, 6 For photometric methods, historically deproteinization has been used to free copper ions from their bond with ceruloplasmin and allow the subsequent binding of total plasma copper to Bathocuproin to form a detectable color complex. 7 This approach has been mostly replaced by photometric assays without deproteinization of samples, which rely on the disassociation of copper from ceruloplasmin with weak acid buffers and the subsequent formation of a blue color complex with 3.5-DiBr-PAESA. 8 The central laboratory of the University Hospital of Halle (UKH) has more than 600 requests for plasma copper analysis per year, the majority from the large psychiatric and neurological departments of the hospital. Such a relatively high number of analysis and the resulting need for timely analysis justified the establishment of a copper assay on our clinical chemistry analyzers, even from an economic perspective. The supplier of clinical chemistry analyzers in the central laboratory of the UKH is Roche Diagnostics (Rotkreuz, Switzerland), which to date has no copper assay in its analytic portfolio, rendering it necessary to use a thirdparty copper assay, which is often provided by small-to medium-scale companies. In 2015, we replaced our clinical chemistry analyzers with a Roche Cobas 8000 modular platform, which also included the application and validation of the LT-SYS in vitro diagnostic copper assay (Labor þ Technik, Berlin, Germany). In this study, we describe the validation and characterization of this copper assay and the method comparison to a previously used BIOMED assay on a Roche Cobas Mira Plus analyzer. The validation procedure was based on several Clinical and Laboratory Standards Institute (CLSI) protocols, with the details given below in the Materials and Methods section.
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Materials and Methods
The LT-SYS quantitative in vitro copper test is a photometric assay based on the 3.5-DiBr-PAESA method without deproteinization of the sample. By adding of acetate buffer, copper ions are freed from ceruloplasmin at a pH of 4.7 and form a stable color complex with the chromogen 3.5-DiBr-PAESA, which can then be measured at 578 (570 to 600) nm wavelength. The color intensity in the sample is directly proportional to the copper concentration in the sample. The LT-SYS copper assay is calibrated with a 2-point calibration according to the specifications and recommendations of the supplier. The calibrator itself is included in the test kit and based on lyophilized human sera (28.0 mmol/L copper target concentration). The characterization of the LT-SYS quantitative in vitro copper assay was carried out on a Roche Cobas c502 modular analyzer. The Cobas c502 module in UKH is part of a fully automated Roche Cobas 8000 platform with a Cobas 8100 pre-analytic unit and 3 Cobas 8000 units.
The Roche Cobas 8000 platform and all its components are operated according to the manufacturer's instructions and manuals, with routine maintenance and quality control procedures.
The BIOMED Kupfer-Hit assay (BIOMED Labordiagnostik GmbH, Oberschleißheim, Germany), which was used as comparative method in this study, is also a 3.5-DiBr-PAESA based method without deproteinization of the sample and functions as described above for the LT-SYS copper assay. The BIOMED Kupfer-Hit assay is calibrated with a 2-point calibration according to the specifications and recommendations of the supplier, with the calibrator being included in the test kit. The test was carried out on a Roche Cobas Mira Plus analyzer, which was operated according to the manufacturer's instructions and manuals, with routine maintenance and quality control procedures.
Imprecision and Bias
Imprecision and bias of the LT-SYS quantitative in vitro copper assay were calculated based on the CLSI EP05-A3 guideline, using a 20 Â 3 experimental design. 9 Two standard commercial controls available from Labor þ Technik (LT-SYS universal control serum, normal and abnormal) were used as sample material in the experiment. The used commercial controls are based on lyophilized human sera and are thus comparable to patient samples, yet have the advantage of a clearly defined target value. The copper target values were 16.3 mmol/L for the low (normal) and 33.8 mmol/L for the high (abnormal) control. Specifications for the standard error (SE) associated with the target values of the used control lots were provided by
In addition to the control material samples, 2 lithium heparin plasma patient sample pools (residual deidentified specimens) were prepared and used for evaluating the imprecision of the assay with regard to plasma samples. While these 2 plasma patient pools clearly have the advantage of being as close to normal patient samples as possible, they lack a clearly defined target value and thus do not allow for testing bias. We aimed at creating 1 plasma pool in the lower and 1 in the upper range of the reference interval for copper (10 to 22 mmol/L). 
Linearity
Linearity was evaluated based on the National Committee for Clinical Laboratory Standards EP06-A guideline. 10 Measurements were carried out for a total of 7 different concentrations, covering the range from 4.08 mmol/L to 33.8 mmol/L of copper, with double measurements at each concentration. We used the standard low-and high-level controls and saline solution (0.9% NaCl) to generate a suitable concentration series.
Limit of Blank and Limit of Detection
Both limit of blank (LoB) and limit of detection (LoD) were estimated based on the CLSI EP17-A2 guideline using a total of 60 blank and 60 low-concentration measurements. 12 For blank samples we used saline solution, which is also recommended by the test supplier for dilutions of patient samples at high concentrations. A total of 5 blank samples were measured over 3 days, with 4 measurements each day. For low-concentration samples, we diluted 5 patient lithium heparin plasma samples (obtained from routine copper analysis) with saline solution (1:15 dilution) to obtain a copper concentration close enough to the LoB to be meaningful for the determination of the LoD (<1 mmol/L). These 5 patient samples were analyzed on 3 days, with 4 measurements each day. Before measurement of samples, the system was calibrated each day to introduce some additional source of variation.
Method Comparison
The newly established LT-SYS copper assay on the Roche Cobas c502 Analyzer was compared to the previously used BIOMED Kupfer-Hit assay (on a Roche Cobas Mira Plus analyzer). Based on the CLSI EP09-A3 guideline, a total of 58 lithium heparin plasma patient samples (residual deidentified specimens) from routine copper analysis were measured on both analyzing systems. 11 To compensate for rarity of samples in pathological low regions (only 1 was available during the period of testing), 10 patient samples were diluted 1:1 with diluent saline solution to obtain copper values <10 mmol/L. By doing so it, was possible to obtain a better resolution of the behavior of the 2 copper assays in the pathological low region.
Statistical Analysis
The imprecision of the LT-SYS copper assay at the 2 chosen control levels was calculated using an analysis of variance. Bias was estimated as relative and absolute bias from the respective target value. Linearity was assessed by a polynomial regression analysis to first-, second-and third-order polynomials. We used regression analysis (both linear and PassingBablok regression) to compare the copper measurements of the 2 assay-analyzer combinations. 14 To illustrate potential differences between the 2 copper assays, we used a Bland-Altman plot (difference plot, both absolute and relative). [15] [16] [17] The limit of agreement (LoA) between the 2 methods was calculated as the interval within which 95% of the differences between the 2 methods fall (mean difference 61.96 SD).
All statistics were carried out using the Analyse-it Method Validation Edition (Analyse-it Software, Ltd, Leeds, UK), an add-in for Microsoft Excel 2010. 18 
Results
Imprecision and Bias
Based on the obtained dataset for the serum-based low (16.3 mmol/L) and high (33.8 mmol/L) control level samples (total n ¼ 120), we calculated a repeatability (within run imprecision) of CV ¼ 0.7% for both the high and low control level, a between day imprecision of CV ¼ 3.2% and 1.3% and a within laboratory (total) imprecision of CV ¼ 3.3% and 1.5% for the low and high control level, respectively. The imprecision of the patient plasma pools was similarly low with a repeatability of CV ¼ 0.9% for the low (mean ¼ 13.2 mmol/L) and 1.2% for the high (mean ¼ 20.2 mmol/L) plasma pool (total n ¼ 120). The between-day imprecision was CV ¼ 1.0% and 1.5%, and the within-laboratory imprecision CV ¼ 1.4% and 1.9% for the low and high plasma pool, respectively. For a detailed distribution of the obtained measurements see Figure 1 . 
Linearity
Over the analyzed measuring range (4.08 to 33.8 mmol/L), no deviation from linearity could be observed, and no second-or third-order polynomial fit was statistically better than a linear fit at the 1% significance level (best linear fit: y ¼ -0.39 þ 1.08x). 
Limit of Blank and Limit of Detection
Method Comparison
Based on the comparison of the 58 patient samples, the 2 copper assays had a high correlation coefficient of r ¼ 0.97 ( Figure 3) . The linear regression fit was y ¼ 1.464 þ 0.795x, and the corresponding PassingBablok regression fit y ¼ 0.948 þ 0.816x. The mean difference was 2.016 mmol/L (95% LoA: -6.01 to 1.89 mmol/L) or 11.2% (95% LoA: -36.5% to 14.1%) between the 2 assays, with the LT-SYS assay measuring lower on the average. The diluted patient samples, which were used to increase sample size in the lower measurement range (<10 mmol/L), did not differ significantly (t-test: t ¼ 0.72; DF ¼ 9; P ¼ .49) from the values expected (average deviation 0.06 mmol/L, SD ¼ 0.26 mmol/L or 0.6%, SD ¼ 1.7%), and thus we did not detect any matrix effects caused by the 1:1 dilution with saline solution. The absolute and relative Bland-Altman plot is given in Figure  4 . As readily identifiable from the difference plots, the absolute difference increases with higher measurement values, while staying more or less constant in relative terms over the measuring range.
Discussion
In this method validation study of the LT-SYS copper assay on a Roche Cobas c502 analyzer, we met all our validation goals and found the LT-SYS copper assay to be suitable for the routine measurement of copper in patient samples in our laboratory. To use internationally comparable standards, we based the validation procedure on several CLSI guidelines intended for method validation and comparison. [9] [10] [11] [12] Overall the validated copper assay exhibited a very low imprecision with only 0.7 to 1.2% CV in repeatability and low to moderate levels of within laboratory (total) imprecision (1.4 to 3.3% CV) for all tested levels and materials (serum and plasma). All measurements for the imprecision estimates were performed under normal routine conditions, by several operators during 2 shifts, including a routine recalibration. The routine recalibration during the measurement of the serum-based control material samples also coincides with a visible shift between days 11 and 12 ( Figure 1) , highlighting the marked effect calibration can have on test results. As such, the testing environment reflects realistic, rather than optimal conditions and thus can be considered reliable.
Estimate of bias was based on the dataset obtained for the serum control material samples with a known target value and resulted in an average bias of 2.3% (absolute 0.38 mmol/ L) for the low and 1.6% (absolute 0.56 mmol/L) for the high control level. Arnaud et al defined quality specifications for determination of copper in human serum or plasma, where 12% bias was given as upper limit for deviation from a target
Figure 2
Distribution of blank and low sample measurements as well as the resulting estimation of the normal distributions and the values of the LoB and LoD.
value, followed by 8% as desirable and 4% as optimal. 19 Therefore, the bias results for the LT-SYS copper assay on the Roche Cobas c502 analyzer in our laboratory fall well under the optimal quality specifications for copper assays as defined by Arnold et al. Nevertheless one has to keep in mind that these estimates for bias and imprecision are based on standard control material, and individual patient samples might deviate from these values. However, since the used standard control materials are based on lyophilized human sera and are not just spiked samples, we consider them a good choice for this type of validation study.
Linearity of the LT-SYS copper assays was evaluated over a measuring range from 4.08 mmol/L to 33.8 mmol/L, covering the pathological low, normal and pathological high sample range. The assay was linear over this range, with no secondor third-order polynomial function fitting better to the obtained dataset. We did refrain from further dilution below 4.08 mmol/L copper to avoid matrix effects and unrealistic linearity estimates. Anyway, samples below this value are already in the highly pathological range, and even if deviation from linearity should occur below this value, the influence on the interpretation should be negligible. Patient samples with copper concentrations >36 mmol/L are routinely diluted 1:1 with saline solution and are reanalyzed, which gives a final linear measuring range for patient samples of up to 76.6 mmol/L copper.
The determination of the LoB and LoD both resulted in very low values of 0.12 and 0.23 mmol/L copper, respectively. In fact, these LoB and LoD estimates are so low, that it is questionable whether any patient samples will ever be measured in this range. Interestingly, the imprecision of the diluted patient samples used for the determination of the LoD was still relatively low, ranging from 6.9% to 10.2% CV (depending on sample) over the 3-day measuring interval. These results again underline the good precision performance of the assay, even in extremely low measuring ranges.
The method comparison of the LT-SYS copper assay on the Roche Cobas c502 analyzer with the previously used BIOMED Kupfer-Hit assay on a Roche Cobas Mira Plus revealed that both assays behaved comparably, with an correlation coefficient of r ¼ 0.97 (linear fit: y ¼ 1.464 þ 0.795x). However the 2 assays also displayed discrepancies; on average the LT-SYS copper assay scored 11.2% lower values than the BIOMED copper assay, with the 95% LoA ranging from -36% to 14%. Thus, given that reference intervals for copper are often not assay or even specimen specific, such differences potentially might impact interpretation of patient results, rendering it difficult to define a clear cut-off for pathological copper concentrations.
Figure 4
Absolute (A) and relative (B) difference plots (Bland-Altman) for the method comparison of the LT-SYS copper assay on a Roche Cobas c502 analyzer with the BIOMED Kupfer-Hit assay on a Roche Cobas Mira Plus analyzer. The black lines denote the 0 deviation, while the blue lines denote the mean deviation and its 95% LoA.
Unfortunately a further interpretation of differences between the 2 copper assays is difficult, since we not only switched from one assay to another, but also transitioned from the older Roche Cobas Mira Plus to a modern, state-of-the-art Roche Cobas c502 analyzer. The differences detected can therefore be attributed to differences between the combinations of analyzers and the assays, or between the analyzers and the assays themselves. The disentanglement of these factors, however, was beyond the scope of this study. LM
